MGNX Earnings Prediction
The chart below shows how MGNX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, MGNX sees a -3.13% change in stock price 10 days leading up to the earnings, and a -4.41% change 10 days following the report. On the earnings day itself, the stock moves by +0.44%. This data can give you a slight idea of what to expect for the next quarter's release.
MGNX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
10.80M
-17.81%
18.60%
Gross Margin
73.85%
-18.88%
-3.79%
Operating Margin
-538.86%
57.43%
-8.73%
Net Margin
-515.55%
-217.84%
-10.07%
EPS
-0.89
-196.74%
5.95%
No Data Available
MGNX Earnings Analysis
MacroGenics, Inc. Corporation (MGNX.O) Earnings Conference Call
Positive
Quarterly Revenue Surge: Macrogenics reported total revenue of $110.7 million for the quarter ended September 30, 2024, compared to total revenue of $10.4 million for the quarter ended September 30, 2023, marking a significant increase due to $100 million in milestones received from IncYTE.
R&D Expense Increase: Research and development expenses were $40.5 million for the quarter ended September 30, 2024, compared to $30.1 million for the quarter ended September 30, 2023, reflecting increased investment in clinical programs.
SG&A Expense Increase: Selling, general and administrative expenses were $14.1 million for the quarter ended September 30, 2024, compared to $12.4 million for the quarter ended September 30, 2023, primarily due to increased stock-based compensation expense and professional fees.
Net Income Surge: Net income was $56.3 million for the quarter ended September 30, 2024, compared to net income of $17.6 million for the quarter ended September 30, 2023, indicating strong financial performance.
Cash and Marketable Securities Balance: Cash, cash equivalents and marketable securities balance as of September 30, 2024, was $200.4 million, compared to $229.8 million as of December 31, 2023, demonstrating a solid financial foundation despite the decrease.
Negative
Quarterly Revenue Surge: Total revenue for the quarter ended September 30, 2024 was $110.7 million, compared to total revenue of $10.4 million for the quarter ended September 30, 2023, indicating a significant increase primarily due to $100 million in milestones received from IncYTE, which may not be sustainable in future quarters.
R&D Expense Increase: Research and development expenses were $40.5 million for the quarter ended September 30, 2024, compared to $30.1 million for the quarter ended September 30, 2023, reflecting increased costs related to the company's preclinical ADC pipeline and clinical trials, which could pressure future profitability.
Rising Operational Costs: Selling, general and administrative expenses were $14.1 million for the quarter ended September 30, 2024, compared to $12.4 million for the quarter ended September 30, 2023, indicating rising operational costs that may impact net income.
Quarterly Net Income Analysis: Net income for the quarter ended September 30, 2024 was $56.3 million, compared to net income of $17.6 million for the quarter ended September 30, 2023, but this included the aforementioned $100 million milestone payment, suggesting underlying operational performance may be weaker than reported.
Liquidity Decline Analysis: Cash, cash equivalents and marketable securities balance as of September 30, 2024 was $200.4 million, compared to $229.8 million as of December 31, 2023, indicating a decline in liquidity that could affect future operational flexibility.
MGNX FAQs
How does MGNX typically perform around its earnings report dates?
Is MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
MGNX Earning Call Sentiment
MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Transcript
1.0x
00:00
00:00
MGNX.O
2.5%Positive
The earnings call reflects strong financial performance with a significant increase in revenue and net income, primarily due to milestone payments. The sale of MARGENZA rights and the anticipated upfront payment further strengthen the financial position. Although there are some risks, such as partnership and market risks, the overall sentiment is positive. Additionally, the Q&A session provided insights into ongoing projects and future expectations, with no major negative surprises. Therefore, the stock price is likely to experience a positive movement in the next two weeks.
